Prolong the "cancer-free survival" of early lung cancer, immunotherapy reduces the risk of recurrence by 34%

From June 4th to June 8th this year, the American Society of Clinical Oncology (ASCO) annual meeting will be held online.

Lung cancer is one of the cancer types that cause the highest number of deaths in the world, and non-small cell lung cancer (NSCLC) patients account for 85% of the total number of lung cancer patients.

IMpower010 is a pivotal phase 3 clinical trial for the treatment of patients with early stage NSCLC.

The results showed that compared with the best supportive therapy, atezolizumab in II-IIIA NSCLC patients with tumor PD-L1 expression> 1%, as an adjuvant therapy, reduced the patient’s risk of disease recurrence or death by 34% (HR=0.

According to a Roche press release, this is the first positive phase 3 clinical result obtained by cancer immunotherapy as an adjuvant lung cancer therapy.

In all patients with stage II-IIIA NSCLC (regardless of PD-L1 expression level), atezolizumab reduced the risk of disease recurrence or death by 21% (HR=0.

Based on the data of patients who received at least one dose of atezolizumab or at least one safety assessment in the best supportive treatment group, the researchers found that the incidence of adverse events of any grade in the atezolizumab group and the best supportive treatment group was 92.

"Although surgery can cure some early-stage lung cancer patients, disease recurrence is still very common.

Note: The original text has been deleted

Reference materials:

[1] Pivotal Phase III data at ASCO show Roche's Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning.

[2] Immunotherapy Delays Disease Recurrence in Patients With Early-Stage, Resected Non-Small Cell Lung Cancer.